Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib adjuvant therapy in high-risk RCC after nephrectomy
CTR20131530Phase 3Suspended
- Sponsor
- Pfizer
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of axitinib in renal cell carcinoma (RCC), sponsored by Pfizer. Started Dec 2014; status: suspended.
02
Drugs
axitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on CTR20131530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131530.